Menu Search
Equities

Autolus Therapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6A3A:STU

Autolus Therapeutics PLC

Actions
  • Price (EUR)1.17
  • Today's Change-0.01 / -0.85%
  • Shares traded0.00
  • 1 Year change-37.43%
  • Beta1.9762
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

  • Revenue in USD (TTM)51.13m
  • Net income in USD-224.80m
  • Incorporated2018
  • Employees647.00
  • Location
    Autolus Therapeutics PLCThe Mediaworks, 191 Wood LaneLONDON W12 7FPUnited KingdomGBR
  • Phone+44 203 829 6230
  • Websitehttps://www.autolus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.